Gazzaruso C, Buscaglia P, Garzaniti A, Bonetti G, Savino S, Mariotti S, Jucci A, Finardi G, Geroldi D
Department of Internal Medicine and Medical Therapeutics, First Medical Clinic, IRCCS Policlinico San Matteo, University of Pavia, Italy.
J Cardiovasc Risk. 1996 Apr;3(2):191-7.
The purpose of the study was to investigate lipoprotein (a) (Lp(a)) levels and apolipoprotein (a) (apo(a)) phenotypes, and their relationship with a family history of coronary heart disease (CHD) in patients with essential hypertension (EH).
One hundred and eight newly diagnosed patients with mild to moderate EH and 159 controls were studied. Lp(a) levels were determined with an ELISA method. Apo(a) isoforms were identified by a capillary immunoblotting technique.
Lp(a) levels and frequency distribution of apo(a) isoforms did not show significant differences between patients and controls. Lp(a) levels in hypertensives with a family history of CHD were significantly higher than in those without a family history of CHD (P < 0.01). Hypertensives with a family history of CHD showed significantly different frequencies of apo(a) isoforms to those without a family history of CHD (P < 0.05). In EH patients with a family history of CHD, apo(a) isoforms of low molecular weight (MW) had a higher prevalence (62.6%), while in hypertensives without a family history of CHD, apo(a) isoforms of high MW were prevalent (81.6%); the difference between the two subgroups was significant (P < 0.001). Multivariate analysis showed that both Lp(a) levels and apo(a) isoforms of low MW are significant variables in distinguishing between the subgroups.
Lp(a) levels and apo(a) phenotypes do not differ between hypertensives and controls. High Lp(a) levels and apo(a) isoforms of low MW are strongly associated with a family history of CHD in hypertensives. The quantification of Lp(a) levels and the characterization of apo(a) phenotypes may be used for assessment of familial predisposition to CHD in hypertensives.
本研究旨在调查原发性高血压（EH）患者的脂蛋白（a）[Lp（a）]水平和载脂蛋白（a）[apo（a）]表型，以及它们与冠心病（CHD）家族史的关系。
对108例新诊断的轻至中度EH患者和159例对照者进行研究。采用酶联免疫吸附测定（ELISA）法测定Lp（a）水平。通过毛细管免疫印迹技术鉴定apo（a）异构体。
患者与对照者之间Lp（a）水平和apo（a）异构体的频率分布无显著差异。有CHD家族史的高血压患者的Lp（a）水平显著高于无CHD家族史的患者（P<0.01）。有CHD家族史的高血压患者与无CHD家族史的患者相比，apo（a）异构体频率有显著差异（P<0.05）。在有CHD家族史的EH患者中，低分子量（MW）的apo（a）异构体患病率较高（62.6%），而在无CHD家族史的高血压患者中，高分子量的apo（a）异构体患病率较高（81.6%）；两个亚组之间的差异显著（P<0.001）。多变量分析表明，Lp（a）水平和低MW的apo（a）异构体都是区分亚组的显著变量。
高血压患者与对照者之间Lp（a）水平和apo（a）表型无差异。高血压患者中高Lp（a）水平和低MW的apo（a）异构体与CHD家族史密切相关。Lp（a）水平的定量和apo（a）表型的特征分析可用于评估高血压患者患CHD的家族易感性。
